Larimar Therapeutics (LRMR) EPS (Basic) Growth (3y) (2016 - 2026)
Powered by 
Analysis
Larimar Therapeutics (LRMR) EPS (Basic) Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 11.71% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 86.03% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -45.60% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 67.51% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | -14.70% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.70% |
| Dec 31, 2025 | -29.38% |
| Sep 30, 2025 | -18.17% |
| Jun 30, 2025 | 2.87% |
| Mar 31, 2025 | -0.21% |
| Dec 31, 2024 | 1.18% |
| Sep 30, 2024 | 32.11% |
| Jun 30, 2024 | 21.07% |
| Mar 31, 2024 | 25.54% |
| Dec 31, 2023 | 35.67% |
| Sep 30, 2023 | 28.58% |
| Jun 30, 2023 | 43.50% |
| Mar 31, 2023 | 56.76% |
| Dec 31, 2022 | 41.14% |
| Sep 30, 2022 | 48.25% |
| Jun 30, 2022 | 25.90% |
| Mar 31, 2022 | 51.41% |
| Dec 31, 2021 | 53.96% |
| Sep 30, 2021 | 42.99% |
| Jun 30, 2021 | 51.49% |